<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1097">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05146869</url>
  </required_header>
  <id_info>
    <org_study_id>HA1118-014</org_study_id>
    <nct_id>NCT05146869</nct_id>
  </id_info>
  <brief_title>A Single-dose and Multiple-dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of DBPR108 Tablets in Type 2 Diabetes Mellitus Patients</brief_title>
  <official_title>A Randomized, Open-Label, Parallel-Cohort, Single-dose and Multiple-dose Phase I Study of DBPR108 Tablets in Type 2 Diabetes Mellitus Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I study to evaluate the safety, tolerability, pharmacokinetics, and&#xD;
      pharmacodynamics of single-dose and multiple-dose of DBPR108 tablets in Type 2 Diabetes&#xD;
      Mellitus Patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics&#xD;
      characteristics, single-dose and multiple-dose of DBPR108 tablets in Chinese Type 2 Diabetes&#xD;
      Mellitus Patients. The 30 eligible patients will be randomized to receive 50 mg, 100 mg, or&#xD;
      200 mg DBPR108 tablets.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak plasma concentration (Cmax) of DBPR108 tablets</measure>
    <time_frame>Day 1-Day 11</time_frame>
    <description>Cmax of DBPR108 tablets will be assessed after single-dose and multiple-dose administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of DBPR108 tablets in plasma</measure>
    <time_frame>Day 1-Day 11</time_frame>
    <description>AUC of DBPR108 tablets will be assessed after single-dose and multiple-dose administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life(t1/2) of DBPR108 tablets</measure>
    <time_frame>Day 1-Day 11</time_frame>
    <description>T1/2 of DBPR108 tablets will be assessed after single-dose and multiple-dose administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of Distribution(Vz/F)of DBPR108 tablets</measure>
    <time_frame>Day 1-Day 11</time_frame>
    <description>Vz/F of DBPR108 tablets will be assessed after single-dose and multiple-dose administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F of DBPR108 tablets</measure>
    <time_frame>Day 1-Day 11</time_frame>
    <description>Apparent clearance(CL/F) of DBPR108 tablets will be assessed single-dose and multiple-dose administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in dipeptidyl peptidase-IV inhibition rate</measure>
    <time_frame>Day 1-Day 11</time_frame>
    <description>Change from baseline in dipeptidyl peptidase-IV inhibition rate will be assessed after single-dose and multiple-dose administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in active glucagon-like peptide1 concentration</measure>
    <time_frame>Day 1-Day 11</time_frame>
    <description>Change from baseline in active glucagon-like peptide1 concentration will be assessed after single-dose and multiple-dose administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of patients with adverse events</measure>
    <time_frame>Throughout the study period, with an average of 1 months</time_frame>
    <description>The number of patients with adverse events as a measure of safety and tolerability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes from baseline in 12-lead electrocardiogram (ECG) examination will be recorded as AEs at each visit time point</measure>
    <time_frame>Within screening period (Day-21 to Day-15), baseline period (Day-7 to Day-1), and before discharge (Day11).</time_frame>
    <description>ECG monitoring includes P-R, QT and QTc intervals in ms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes from baseline in vital signs examination will be recorded as AEs at each visit time point.</measure>
    <time_frame>Throughout the study period, with an average of 1 months</time_frame>
    <description>Vital signs monitoring includes respiratory rate and pulse in times per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes from baseline in vital signs examination will be recorded as AEs at each visit time point.</measure>
    <time_frame>Throughout the study period, with an average of 1 months</time_frame>
    <description>Vital signs monitoring includes systolic blood pressure and diastolic blood pressure in mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes from baseline in vital signs examination will be recorded as AEs at each visit time point.</measure>
    <time_frame>Throughout the study period, with an average of 1 months</time_frame>
    <description>Vital signs monitoring includes body temperature in degrees Celsius</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes from baseline in physical examination will be recorded as AEs at each visit time point.</measure>
    <time_frame>Within screening period (Day-21 to Day-15), baseline period (Day-7 to Day-1), and before discharge (Day11).</time_frame>
    <description>Physical examination includes mucocutaneous, lymphonodus, head and neck,chest, abdomen, spinal column, musculoskeletal, nervous system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes from baseline in routine blood test will be recorded as AEs at each visit time point.</measure>
    <time_frame>Within screening period (Day-21 to Day-15), baseline period (Day-7 to Day-1), and before discharge (Day11)</time_frame>
    <description>Routine blood test includes white blood cell count, platelet, neutrophilic granulocyte count, lymphocyte count and monocyte count in 10^9 /L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes from baseline in blood biochemistry test will be recorded as AEs at each visit time point.recorded as AEs at each visit time point.</measure>
    <time_frame>Within screening period (Day-21 to Day-15), baseline period (Day-7 to Day-1), and before discharge (Day11)</time_frame>
    <description>Blood biochemistry test includes total protein, albumin and albumin in g/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes from baseline in blood biochemistry test will be recorded as AEs at each visit time point.recorded as AEs at each visit time point.</measure>
    <time_frame>Within screening period (Day-21 to Day-15), baseline period (Day-7 to Day-1), and before discharge (Day11)</time_frame>
    <description>Blood biochemistry test includes alanine aminotransferase, aspartate aminotransferase, amylase, alkaline phosphatase and in U/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes from baseline in blood biochemistry test will be recorded as AEs at each visit time point.recorded as AEs at each visit time point.</measure>
    <time_frame>Within screening period (Day-21 to Day-15), baseline period (Day-7 to Day-1), and before discharge (Day11)</time_frame>
    <description>Blood biochemistry test includes ureophil, glucose, triglyceridein, total cholesterol, high-density lipoprotein, low-density lipoprotein, sodium, potassium, chlorine, calcium in mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes from baseline in blood biochemistry test will be recorded as AEs at each visit time point.recorded as AEs at each visit time point.</measure>
    <time_frame>Within screening period (Day-21 to Day-15), baseline period (Day-7 to Day-1), and before discharge (Day 11)</time_frame>
    <description>Blood biochemistry test includes total bilirubin and serum creatinine in umol/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes from baseline in routine urine test will be recorded as AEs at each visit time point.</measure>
    <time_frame>Within screening period (Day-21 to Day-15), baseline period (Day-7 to Day-1), and before discharge (Day11)</time_frame>
    <description>Routine urine test includes the count of leukocyte, and red blood cell in high-power field.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes from baseline in routine urine test will be recorded as AEs at each visit time point.</measure>
    <time_frame>Within screening period (Day-21 to Day-15), baseline period (Day-7 to Day-1), and before discharge (Day11)</time_frame>
    <description>Routine urine test includes glucose, protein, ketonein in negative or positive.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>50 mg DBPR108 tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 patients will be randomized to receive 50 mg DBPR108 tablets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg DBPR108 tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 patients will be randomized to receive 100 mg DBPR108 tablets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg DBPR108 tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 patients will be randomized to receive 200 mg DBPR108 tablets.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DBPR108 tablets</intervention_name>
    <description>DBPR108 tablets, oral, once daily on Day 1 and Day 3-9 for a total of 8 doses.</description>
    <arm_group_label>100 mg DBPR108 tablets</arm_group_label>
    <arm_group_label>200 mg DBPR108 tablets</arm_group_label>
    <arm_group_label>50 mg DBPR108 tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who meet the World Health Organization (WHO) (1999) criteria for the&#xD;
             diagnosis and classification criteria for type 2 diabetes mellitus;&#xD;
&#xD;
          2. 18 ≤ age ≤ 75 years old, male or female;&#xD;
&#xD;
          3. Body mass index (BMI) within the range of 19-35 kg/m^2 (inclusive), BMI = weight (kg)&#xD;
             / height^2 (m^2);&#xD;
&#xD;
          4. 7.0% ≤Hemoglobin A1c (HbA1c) ≤ 9.5%;&#xD;
&#xD;
          5. Patients who voluntarily participate in the study and sign the informed consent form;&#xD;
&#xD;
          6. Patients who agree to use contraception from the signing of the informed consent form&#xD;
             until 1 month after the end of the last medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Fasting plasma glucose (FPG) &gt; 13.9 mmol/L;&#xD;
&#xD;
          2. The investigator determines that the patients need to use insulin therapy;&#xD;
&#xD;
          3. Patients with acute or serious complications of diabetes (including diabetic&#xD;
             ketoacidosis, hyperosmotic nonketotic diabetic coma, lactic acidosis and hypoglycemia&#xD;
             coma);&#xD;
&#xD;
          4. History of severe hypoglycemia (hypoglycemia with severe cognitive impairment and&#xD;
             requiring other measures to help recover);&#xD;
&#xD;
          5. History of acute or chronic pancreatitis, or related diseases that are most common&#xD;
             cause of acute pancreatitis (such as recurrent cholelithiasis, etc.);&#xD;
&#xD;
          6. History of allergy to DPP-4 inhibitors or the investigator determines that the&#xD;
             patients may be allergic to investigational drug;&#xD;
&#xD;
          7. Patients with untreated hyperthyroidism and other diseases, which may affect blood&#xD;
             glucose;&#xD;
&#xD;
          8. Patients who have used other hypoglycemic drugs within 14 days before the first dose;&#xD;
             or patients who are not suitable for this study as determined by the investigator due&#xD;
             to taking other hypoglycemic drugs;&#xD;
&#xD;
          9. Patients with inflammatory bowel disease, partial intestinal obstruction or chronic&#xD;
             bowel disease related to obvious digestive and absorption disorders;&#xD;
&#xD;
         10. Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) &gt; 3 * upper limit&#xD;
             of normal (ULN), or total bilirubin &gt; 1.5 *ULN;&#xD;
&#xD;
         11. Abnormal renal function: serum creatinine&gt;1.5 * ULN; or eGFR&lt; 45 mL/min/1.73m^2;&#xD;
&#xD;
         12. White blood cells (WBC) &lt; 3.0 *10^9/L and neutrophil count of peripheral blood &lt; 1.5 *&#xD;
             10^9/L; hemoglobin &lt; 100 g / L; triglyceride &gt; 5.7 mmol/L;&#xD;
&#xD;
         13. Patients who have the second or third degree atrioventricular block, long Q-T&#xD;
             syndrome, or QTc&gt;500 ms without cardiac pacemaker;&#xD;
&#xD;
         14. Patients with any one of HBsAg, hepatitis C antibody, anti-HIV antibody and antibody&#xD;
             of treponema pallidum positive;&#xD;
&#xD;
         15. Female patients of childbearing age with pregnant test positive or lactating women;&#xD;
&#xD;
         16. History of alcohol or drug abuse within 3 months before screening, alcohol abuse is&#xD;
             average alcohol intake more than 14 units alcohol (1 unit=12 ounces or 360 mL of&#xD;
             beer,1.5 ounces or 45 mL spirits with 40% alc/vol, 5 ounces or 150 mL grape wine); or&#xD;
             intake any other products containing alcohol within 2 days before the first&#xD;
             administration of investigational product;&#xD;
&#xD;
         17. Patients who smoke more than 5 cigarettes per day within 3 months prior to screening;&#xD;
&#xD;
         18. Patients with consumption of grapefruit juice, methylxanthine-rich food or beverage&#xD;
             (such as coffee, tea, cola, chocolate, energy drinks) within 2 days before the first&#xD;
             administration in treatment period , or patients who have strenuous exercise, or have&#xD;
             other factors affecting drug absorption, distribution, metabolism, excretion, etc;&#xD;
&#xD;
         19. Participation in other clinical trials or administration of any other investigational&#xD;
             drugs or devices within 3 months before screening;&#xD;
&#xD;
         20. Patients with the following diseases:&#xD;
&#xD;
               1. Serious dysrhythmias, obvious left ventricular dysfunction, New York Heart&#xD;
                  Association (NYHA) functional class III or IV;&#xD;
&#xD;
               2. History of unstable angina pectoris, myocardial infarction, or other high-risk&#xD;
                  coronary artery diseases;&#xD;
&#xD;
               3. Uncontrolled hypertension, systolic pressure ≥160 mmHg or diastolic pressure ≥100&#xD;
                  mmHg;&#xD;
&#xD;
               4. History of cancer , organ transplantation;&#xD;
&#xD;
               5. History of epilepsy, psychosis, severe depression, etc.&#xD;
&#xD;
         21. Not suitable for this study as determined by the investigator due to other reasons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yang Lin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Anzhen Hospital, No.2, Anzhen Road, Chaoyang District, Beijing, China</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shan Jing, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Anzhen Hospital, No.2, Anzhen Road, Chaoyang District, Beijing, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yang Lin, PhD</last_name>
    <phone>+86-18910778667</phone>
    <email>linyang@anzhengcp.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shan Jing, PhD</last_name>
    <phone>+86-13661610502</phone>
    <email>jingshan@anzhengcp.com</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 12, 2021</study_first_submitted>
  <study_first_submitted_qc>November 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2021</study_first_posted>
  <last_update_submitted>November 23, 2021</last_update_submitted>
  <last_update_submitted_qc>November 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

